Nitrate therapy: New aspects concerning molecular action and tolerance

Circulation

Volumn 123, Issue 19, 2011, Pages 2132-2144

  Münzel, Thomas ^a   Daiber, Andreas ^a   Gori, Tommaso ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

endothelial cells; nitric oxide; nitric oxide synthase; nitroglycerin; oxidative stress

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIOXIDANT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; NITRIC OXIDE; ORGANIC NITRATE; THIOL GROUP;

ALCOHOL METABOLISM; BIOTRANSFORMATION; DRUG CROSS TOLERANCE; DRUG TOLERANCE; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HEMODYNAMICS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; THORAX PAIN; THROMBOCYTE AGGREGATION;

CARDIOVASCULAR DISEASES; DRUG TOLERANCE; ENDOTHELIUM, VASCULAR; HUMANS; NITRATES; OXIDATIVE STRESS;

EID: 79957505763     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.981407     Document Type: Review

References (117)

1. Parker JO Parker JD. Neurohormonal activation during nitrate therapy: a possible mechanism for tolerance. Am J Cardiol. 1992;70:93B-97B.
2. Munzel T Sayegh H Freeman BA Tarpey MM Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: a novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995;95:187-194.
3. Munzel T Giaid A Kurz S Stewart DJ Harrison DG. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci USA. 1995;92:5244-5248.
4. Gori T Mak SS Kelly S Parker JD. Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J Am Coll Cardiol. 2001;38:1096-1101.
5. Mayer B Kleschyov AL Stessel H Russwurm M Munzel T Koesling D Schmidt K. Inactivation of soluble guanylate cyclase by stoichiometric S-nitrosation. Mol Pharmacol. 2009;75:886-891.
6. Gori T Parker JD. Nitrate tolerance: a unifying hypothesis. Circulation. 2002;106:2510-2513.
7. Munzel T Daiber A Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97:618-628.
8. Munzel T Sinning C Post F Warnholtz A Schulz E. Pathophysiology diagnosis and prognostic implications of endothelial dysfunction. Ann Med. 2008;40:180-196.
9. Gori T Daiber A. Non-hemodynamic effects of organic nitrates and the distinctive characteristics of pentaerithrityl tetranitrate. Am J Cardiovasc Drugs. 2009;9:7-15.
10. Chirkov YY Naujalis JI Barber S Sage RE Gove DW Brealey JK Horowitz JD. Reversal of human platelet aggregation by low concentrations of nitroglycerin in vitro in normal subjects. Am J Cardiol. 1992;70:802-806.
11. Chirkov YY Horowitz JD. N-acetylcysteine potentiates nitroglycerininduced reversal of platelet aggregation. J Cardiovasc Pharmacol. 1996; 28:375-380.
12. Anfossi G Mularoni EM Burzacca S Ponziani MC Massucco P Mattiello L Cavalot F Trovati M. Platelet resistance to nitrates in obesity and obese NIDDM and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care. 1998;21:121-126.
13. Chirkov YY Holmes AS Willoughby SR Stewart S Wuttke RD Sage PR Horowitz JD. Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J Am Coll Cardiol. 2001;37:1851-1857.
14. Anderson RA Ellis GR Evans LM Morris K Chirkov YY Horowitz JD Jackson SK Rees A Lewis MJ Frenneaux MP. Platelet nitrate responsiveness in fasting and postprandial type 2 diabetes. Diab Vasc Dis Res. 2005;2:88-93.
15. McVeigh G Brennan G Hayes R Johnston D. Primary nitrate tolerance in diabetes mellitus. Diabetologia. 1994;37:115-117.
16. Munzel T Feil R Mulsch A Lohmann SM Hofmann F Walter U. Physiology and pathophysiology of vascular signaling controlled by guanosine 3-5-cyclic monophosphate-dependent protein kinase [corrected]. Circulation. 2003;108:2172-2183.
17. Aoki H Inoue M Mizobe T Harada M Imai H Kobayashi A. Platelet function is inhibited by nitric oxide liberation during nitroglycerininduced hypotension anaesthesia. Br J Anaesth. 1997;79:476-481.
18. Booth BP Tabrizi-Fard MA Fung H. Calcitonin gene-related peptidedependent vascular relaxation of rat aorta: an additional mechanism for nitroglycerin. Biochem Pharmacol. 2000;59:1603-1609.
19. Chirkov YY Holmes AS Chirkova LP Horowitz JD. Nitrate resistance in platelets from patients with stable angina pectoris. Circulation. 1999; 100:129-134.
20. Sogo N Magid KS Shaw CA Webb DJ Megson IL. Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun. 2000;279:412-419.
21. Ellis GR Anderson RA Chirkov YY Morris-Thurgood J Jackson SK Lewis MJ Horowitz JD Frenneaux MP. Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure. J Cardiovasc Pharmacol. 2001;37: 564-570.
22. Palmer RM Ferrige AG Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
23. Kleschyov AL Oelze M Daiber A Huang Y Mollnau H Schulz E Sydow K Fichtlscherer B Mulsch A Munzel T. Does nitric oxide mediate the vasodilator activity of nitroglycerin? Circ Res. 2003;93: e104-e112.
24. Nunez C Victor VM Tur R Alvarez-Barrientos A Moncada S Esplugues JV D'Ocon P. Discrepancies between nitroglycerin and NO-releasing drugs on mitochondrial oxygen consumption vasoactivity and the release of NO. Circ Res. 2005;97:1063-1069.
25. Agvald P Adding LC Gustafsson LE Persson MG. Nitric oxide generation tachyphylaxis and cross-tachyphylaxis from nitrovasodilators in vivo. Eur J Pharmacol. 1999;385:137-145.
26. Pautz A Rauschkolb P Schmidt N Art J Oelze M Wenzel P Forstermann U Daiber A Kleinert H. Effects of nitroglycerin or pentaerithrityl tetranitrate treatment on the gene expression in rat hearts: evidence for cardiotoxic and cardioprotective effects. Physiol Genomics. 2009;38:176-185.
27. Chen Z Zhang J Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA. 2002;99: 8306-8311.
28. Sydow K Daiber A Oelze M Chen Z August M Wendt M Ullrich V Mulsch A Schulz E Keaney JF Jr Stamler JS Munzel T. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest. 2004;113: 482-489.
29. Zhang J Chen Z Cobb FR Stamler JS. Role of mitochondrial aldehyde dehydrogenase in nitroglycerin-induced vasodilation of coronary and systemic vessels: an intact canine model. Circulation. 2004;110: 750-755.
30. Chen Z Foster MW Zhang J Mao L Rockman HA Kawamoto T Kitagawa K Nakayama KI Hess DT Stamler JS. An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci USA. 2005;102:12159-12164.
31. Daiber A Oelze M Coldewey M Bachschmid M Wenzel P Sydow K Wendt M Kleschyov AL Stalleicken D Ullrich V Mulsch A Munzel T. Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates. Mol Pharmacol. 2004;66:1372-1382.
32. Hink U Daiber A Kayhan N Trischler J Kraatz C Oelze M Mollnau H Wenzel P Vahl CF Ho KK Weiner H Munzel T. Oxidative inhibition of the mitochondrial aldehyde dehydrogenase promotes nitroglycerin tolerance in human blood vessels. J Am Coll Cardiol. 2007;50: 2226-2232.
33. Mackenzie IS Maki-Petaja KM McEniery CM Bao YP Wallace SM Cheriyan J Monteith S Brown MJ Wilkinson IB. Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans. Arterioscler Thromb Vasc Biol. 2005;25:1891-1895.
34. Elkayam U Kulick D McIntosh N Roth A Hsueh W Rahimtoola SH. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation. 1987;76:577-584.
35. Fink B Bassenge E. Association between vascular tolerance and platelet upregulation: comparison of nonintermittent administration of pentaerithrityltetranitrate and glyceryltrinitrate. J Cardiovasc Pharmacol. 2002; 40:890-897.
36. Chirkov YY Chirkova LP Horowitz JD. Nitroglycerin tolerance at the platelet level in patients with angina pectoris. Am J Cardiol. 1997;80: 128-131.
37. Booth BP Jacob S Bauer JA Fung HL. Sustained antiplatelet properties of nitroglycerin during hemodynamic tolerance in rats. J Cardiovasc Pharmacol. 1996;28:432-438.
38. Holmes AS Chirkov YY Willoughby SR Poropat S Pereira J Horowitz JD. Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance. Br J Clin Pharmacol. 2005;60:355-363.
39. McVeigh GE Hamilton P Wilson M Hanratty CG Leahey WJ Devine AB Morgan DG Dixon LJ McGrath LT. Platelet nitric oxide and superoxide release during the development of nitrate tolerance: effect of supplemental ascorbate. Circulation. 2002;106:208-213.
40. Parker JD Parker AB Farrell B Parker JO. Intermittent transdermal nitroglycerin therapy: decreased anginal threshold during the nitrate-free interval. Circulation. 1995;91:973-978.
41. Parker JD Farrell B Fenton T Cohanim M Parker JO. Counterregulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation. 1991;84:2336-2345.
42. Munzel T Heitzer T Kurz S Harrison DG Luhman C Pape L Olschewski M Just H. Dissociation of coronary vascular tolerance and neurohormonal adjustments during long-term nitroglycerin therapy in patients with stable coronary artery disease. J Am Coll Cardiol. 1996; 27:297-303.
43. Packer M Lee WH Kessler PD Gottlieb SS Medina N Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987;317:799-804.
44. Gori T Floras JS Parker JD. Effects of nitroglycerin treatment on baroreflex sensitivity and short-term heart rate variability in humans. J Am Coll Cardiol. 2002;40:2000-2005.
45. Heitzer T Just H Brockhoff C Meinertz T Olschewski M Munzel T. Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril. J Am Coll Cardiol. 1998;31: 83-88.
46. Warnholtz A Mollnau H Heitzer T Kontush A Moller-Bertram T Lavall D Giaid A Beisiegel U Marklund SL Walter U Meinertz T Munzel T. Adverse effects of nitroglycerin treatment on endothelial function vascular nitrotyrosine levels and cGMP-dependent protein kinase activity in hyperlipidemic Watanabe rabbits. J Am Coll Cardiol. 2002;40:1356-1363.
47. Hink U Oelze M Kolb P Bachschmid M Zou MH Daiber A Mollnau H August M Baldus S Tsilimingas N Walter U Ullrich V Münzel T. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol. 2003;42:1826-1834.
48. Schulz E Tsilimingas N Rinze R Reiter B Wendt M Oelze M Woelken-Weckmuller S Walter U Reichenspurner H Meinertz T Munzel T. Functional and biochemical analysis of endothelial (dys) function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation. 2002;105:1170-1175.
49. Sage PR De la Lande IS Stafford I Bennett CL Phillipov G Stubberfield J Horowitz JD. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation. 2000; 102:2810-2815.
50. Jurt U Gori T Ravandi A Babaei S Zeman P Parker JD. Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study. J Am Coll Cardiol. 2001;38:854-859.
51. McGrath LT Dixon L Morgan DR McVeigh GE. Production of 8-epi prostaglandin F(2alpha) in human platelets during administration of organic nitrates. J Am Coll Cardiol. 2002;40:820-825.
52. Gori T Parker JD. The puzzle of nitrate tolerance: pieces smaller than we thought? Circulation. 2002;106:2404-2408.
53. Mulsch A Bauersachs J Schafer A Stasch JP Kast R Busse R. Effect of YC-1 an NO-independent superoxide-sensitive stimulator of soluble guanylyl cyclase on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol. 1997;120:681-689.
54. Esplugues JV Rocha M Nunez C Bosca I Ibiza S Herance JR Ortega A Serrador JM D'Ocon P Victor VM. Complex I dysfunction and tolerance to nitroglycerin: an approach based on mitochondrial-targeted antioxidants. Circ Res. 2006;99:1067-1075.
55. Daiber A Oelze M Sulyok S Coldewey M Schulz E Treiber N Hink U Mulsch A Scharffetter-Kochanek K Munzel T. Heterozygous deficiency of manganese superoxide dismutase in mice (Mn-SOD-/-): a novel approach to assess the role of oxidative stress for the development of nitrate tolerance. Mol Pharmacol. 2005;68:579-588.
56. Needleman P Hunter FE Jr. Effects of organic nitrates on mitochondrial respiration and swelling: possible correlations with the mechanism of pharmacologic action. Mol Pharmacol. 1966;2:134-143.
57. Daiber A. Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim Biophys Acta. 2010;1797:897-906.
58. Wenzel P Hink U Oelze M Schuppan S Schaeuble K Schildknecht S Ho KK Weiner H Bachschmid M Munzel T Daiber A. Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity: implications for mitochondrial oxidative stress and nitrate tolerance. J Biol Chem. 2007;282:792-799.
59. Wenzl MV Beretta M Gorren AC Zeller A Baral PK Gruber K Russwurm M Koesling D Schmidt K Mayer B. Role of the general base Glu-268 in nitroglycerin bioactivation and superoxide formation by aldehyde dehydrogenase-2. J Biol Chem. 2009;284:19878-19886.
60. Wenzel P Mollnau H Oelze M Schulz E Wickramanayake JM Muller J Schuhmacher S Hortmann M Baldus S Gori T Brandes RP Munzel T Daiber A. First evidence for a crosstalk between mitochondrial and NADPH oxidase-derived reactive oxygen species in nitroglycerintriggered vascular dysfunction. Antioxid Redox Signal. 2008;10: 1435-1447.
61. Schulz E Jansen T Wenzel P Daiber A Munzel T. Nitric oxide tetrahydrobiopterin oxidative stress and endothelial dysfunction in hypertension. Antioxid Redox Signal. 2008;10:1115-1126.
62. Schmidt K Rehn M Stessel H Wolkart G Mayer B. Evidence against tetrahydrobiopterin depletion of vascular tissue exposed to nitric oxide/ superoxide or nitroglycerin. Free Radic Biol Med. 2010;48:145-152.
63. Munzel T Li H Mollnau H Hink U Matheis E Hartmann M Oelze M Skatchkov M Warnholtz A Duncker L Meinertz T Forstermann U. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression NOS III-mediated superoxide production and vascular NO bioavailability. Circ Res. 2000;86:E7-E12.
64. Gruhn N Aldershvile J Boesgaard S. Tetrahydrobiopterin improves endothelium-dependent vasodilation in nitroglycerin-tolerant rats. Eur J Pharmacol. 2001;416:245-249.
65. Caramori PR Adelman AG Azevedo ER Newton GE Parker AB Parker JD. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol. 1998;32: 1969-1974.
66. Thomas GR DiFabio JM Gori T Parker JD. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol. 2007;49:1289-1295.
67. Schnorbus B Schiewe R Ostad MA Medler C Wachtlin D Wenzel P Daiber A Munzel T Warnholtz A. Effects of pentaerythritol tetranitrate on endothelial function in coronary artery disease: results of the PENTA study. Clin Res Cardiol. 2009;99:115-124.
68. Sekiya M Sato M Funada J Ohtani T Akutsu H Watanabe K. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol. 2005;46:63-67.
69. Sayed N Kim DD Fioramonti X Iwahashi T Duran WN Beuve A. Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ Res. 2008;103: 606-614.
70. Kukovetz WR Holzmann S. Tolerance and cross-tolerance between SIN-1 and nitric oxide in bovine coronary arteries. J Cardiovasc Pharmacol. 1989;14(suppl 11):S40-S44.
71. Dalal JJ Parker JO. Nitrate cross-tolerance: effect of sublingual isosorbide dinitrate and nitroglycerin during sustained nitrate therapy. Am J Cardiol. 1984;54:286-288.
72. Kim D Rybalkin SD Pi X Wang Y Zhang C Munzel T Beavo JA Berk BC Yan C. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation. 2001; 104:2338-2343.
73. DiFabio J Ji Y Vasiliou V Thatcher GR Bennett BM. Role of mitochondrial aldehyde dehydrogenase in nitrate tolerance. Mol Pharmacol. 2003;64:1109-1116.
74. Gori T Saunders L Ahmed S Parker JD. Effect of folic acid on nitrate tolerance in healthy volunteers: differences between arterial and venous circulation. J Cardiovasc Pharmacol. 2003;41:185-190.
75. Azevedo ER Schofield AM Kelly S Parker JD. Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine. J Am Coll Cardiol. 2001;37:505-509.
76. Gori T Burstein JM Ahmed S Miner SE Al-Hesayen A Kelly S Parker JD. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation. 2001;104:1119-1123.
77. Gori T Harvey P Floras JS Parker JD. Continuous therapy with nitroglycerin impairs endothelium-dependent vasodilation but does not cause tolerance in conductance arteries: a human in vivo study. J Cardiovasc Pharmacol. 2004;44:601-606.
78. Heitzer T Schlinzig T Krohn K Meinertz T Munzel T. Endothelial dysfunction oxidative stress and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673-2678.
79. Ahlner J Andersson RG Torfgard K Axelsson KL. Organic nitrate esters: clinical use and mechanisms of actions. Pharmacol Rev. 1991; 43:351-423.
80. Gori T Al-Hesayen A Jolliffe C Parker JD. Comparison of the effects of pentaerythritol tetranitrate and nitroglycerin on endotheliumdependent vasorelaxation in male volunteers. Am J Cardiol. 2003;91: 1392-1394.
81. Hacker A Muller S Meyer W Kojda G. The nitric oxide donor pentaerythritol tetranitrate can preserve endothelial function in established atherosclerosis. Br J Pharmacol. 2001;132:1707-1714.
82. Oberle S Abate A Grosser N Hemmerle A Vreman HJ Dennery PA Schneider HT Stalleicken D Schroder H. Endothelial protection by pentaerithrityl trinitrate: bilirubin and carbon monoxide as possible mediators. Exp Biol Med (Maywood). 2003;228:529-534.
83. Wenzel P Oelze M Coldewey M Hortmann M Seeling A Hink U Mollnau H Stalleicken D Weiner H Lehmann J Li H Forstermann U Munzel T Daiber A. Heme oxygenase-1: a novel key player in the development of tolerance in response to organic nitrates. Arterioscler Thromb Vasc Biol. 2007;27:1729-1735.
84. Schuhmacher S Wenzel P Schulz E Oelze M Mang C Kamuf J Gori T Jansen T Knorr M Karbach S Hortmann M Mathner F Bhatnagar A Forstermann U Li H Munzel T Daiber A. Pentaerythritol tetranitrate improves angiotensin II-induced vascular dysfunction via induction of heme oxygenase-1. Hypertension. 2010;55:897-904.
85. Parker JD. Potential problems with intermittent nitrate therapy. Can J Cardiol. 1996;12(suppl C):22C-24C.
86. Freedman SB Daxini BV Noyce D Kelly DT. Intermittent transdermal nitrates do not improve ischemia in patients taking beta-blockers or calcium antagonists: potential role of rebound ischemia during the nitrate-free period. J Am Coll Cardiol. 1995;25:349-355.
87. Pepine CJ Lopez LM Bell DM Handberg-Thurmond EM Marks RG McGorray S. Effects of intermittent transdermal nitroglycerin on occurrence of ischemia after patch removal: results of the Second Trans-dermal Intermittent Dosing Evaluation Study (TIDES-II). J Am Coll Cardiol. 1997;30:955-961.
88. Munzel T Mollnau H Hartmann M Geiger C Oelze M Warnholtz A Yehia AH Forstermann U Meinertz T. Effects of a nitrate-free interval on tolerance vasoconstrictor sensitivity and vascular superoxide production. J Am Coll Cardiol. 2000;36:628-634.
89. Hebert D Lam JY. Nitroglycerin rebound associated with vascular rather than platelet hypersensitivity. J Am Coll Cardiol. 2000;36: 2311-2316.
90. Pasch T Kleierl-Lindner C Gotz H Pichl J. Rebound hypertension after controlled hypotension and its prevention by captopril [in German]. Anaesthesist. 1986;35:66-72.
91. Ishikawa K Yamamoto T Kanamasa K Hayashi T Takenaka T Kimura A Miyataka M Yabushita H Kitayama K. Intermittent nitrate therapy for prior myocardial infarction does not induce rebound angina nor reduce cardiac events. Intern Med. 2000;39:1020-1026.
92. Needleman P Johnson EM Jr. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther. 1973;184:709-715.
93. Munzel T Holtz J Mulsch A Stewart DJ Bassenge E. Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo but tolerance-independent interactions exist. Circulation. 1989;79:188-197.
94. Levy WS Katz RJ Wasserman AG. Methionine restores the venodilative response to nitroglycerin after the development of tolerance. J Am Coll Cardiol. 1991;17:474-479.
95. Munzel T Mulsch A Holtz J Just H Harrison DG Bassenge E. Mechanisms of interaction between the sulfhydryl precursor L-methionine and glyceryl trinitrate. Circulation. 1992;86:995-1003.
96. Bassenge E Fink N Skatchkov M Fink B. Dietary supplement with vitamin C prevents nitrate tolerance. J Clin Invest. 1998;102:67-71.
97. Bassenge E Fink B. Tolerance to nitrates and simultaneous upregulation of platelet activity prevented by enhancing antioxidant state. Naunyn Schmiedebergs Arch Pharmacol. 1996;353:363-367.
98. Milone SD Pace-Asciak CR Reynaud D Azevedo ER Newton GE Parker JD. Biochemical hemodynamic and vascular evidence concerning the free radical hypothesis of nitrate tolerance. J Cardiovasc Pharmacol. 1999;33:685-690.
99. Munzel T Gori T Bruno RM Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J. 2010;31:2741-2748.
100. Berkenboom G Brekine D Unger P Grosfils K Staroukine M Fontaine J. Chronic angiotensin-converting enzyme inhibition and endothelial function of rat aorta. Hypertension. 1995;26:738-743.
101. Mehra A Ostrzega E Shotan A Johnson JV Elkayam U. Persistent hemodynamic improvement with short-term nitrate therapy in patients with chronic congestive heart failure already treated with captopril. Am J Cardiol. 1992;70:1310-1314.
102. Frame MD Fox RJ Kim D Mohan A Berk BC Yan C. Diminished arteriolar responses in nitrate tolerance involve ROS and angiotensin II. Am J Physiol Heart Circ Physiol. 2002;282:H2377-H2385.
103. Milone SD Azevedo ER Forster C Parker JD. The angiotensin II-receptor antagonist losartan does not prevent hemodynamic or vascular tolerance to nitroglycerin. J Cardiovasc Pharmacol. 1999;34: 645-650.
104. Cohn JN. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Eur Heart J. 1988;9(suppl A):171-173.
105. Cohn JN Tam SW Anand IS Taylor AL Sabolinski ML Worcel M. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a welltreated black population with heart failure: results from A-HeFT. J Card Fail. 2007;13:331-339.
106. Gogia H Mehra A Parikh S Raman M Ajit-Uppal J Johnson JV Elkayam U. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:1575-1580.
107. Parker JD Parker AB Farrell B Parker JO. The effect of hydralazine on the development of tolerance to continuous nitroglycerin. J Pharmacol Exp Ther. 1997;280:866-875.
108. Daiber A Oelze M Coldewey M Kaiser K Huth C Schildknecht S Bachschmid M Nazirisadeh Y Ullrich V Mulsch A Munzel T Tsilimingas N. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun. 2005;338:1865-1874.
109. M̈unzel T Kurz S Rajagopalan S Thoenes M Berrington WR Thompson JA Freeman BA Harrison DG. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest. 1996;98: 1465-1470.
110. Fink B Schwemmer M Fink N Bassenge E. Tolerance to nitrates with enhanced radical formation suppressed by carvedilol. J Cardiovasc Pharmacol. 1999;34:800-805.
111. Watanabe H Kakihana M Ohtsuka S Sugishita Y. Preventive effects of carvedilol on nitrate tolerance: a randomized double-blind placebocontrolled comparative study between carvedilol and arotinolol. J Am Coll Cardiol. 1998;32:1201-1206.
112. Fontaine D Otto A Fontaine J Berkenboom G. Prevention of nitrate tolerance by long-term treatment with statins. Cardiovasc Drugs Ther. 2003;17:123-128.
113. Liuni A Luca M Uxa A Mariani J Gori T Parker J. Coadministration of atorvastatin prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in humans in vivo. J Am Coll Cardiol. 2011;57:93-98.
114. Nakamura Y Moss AJ Brown MW Kinoshita M Kawai C. Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies: Multicenter Myocardial Ischemia Research Group. Am Heart J. 1999;138:577-585.
115. Gori T Parker JD. Nitrate-induced toxicity and preconditioning: a rationale for reconsidering the use of these drugs. J Am Coll Cardiol. 2008;52:251-254.
116. Gori T Di Stolfo G Sicuro S Dragoni S Lisi M Forconi S Parker JD. Nitroglycerin protects the endothelium from ischaemia and reperfusion: human mechanistic insight. Br J Clin Pharmacol. 2007;64:145-150.
117. Ambrosio G Del Pinto M Tritto I Agnelli G Bentivoglio M Zuchi C Anderson FA Gore JM Lopez-Sendon J Wyman A Kennelly BM Fox KA. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52693 patients in the Global Registry of Acute Coronary Events. Eur Heart J. 31:430-438.